Background:
To analyse the uptake and utilisation of the patient support program (PSP) and home infusion service run by Bristol Myers Squibb Australia (BMSA). Analysis will also assess the impact of the COVID-19 pandemic period, and describe protocol changes implemented as a result of the pandemic.
This alternative model of care provides patients with access to a nurse support service that can administer infusions in the home or other suitable location.
Methods:
Retrospective review of PSP enrolment data from the PSP database and comparison of pre-COVID-19 protocols with during COVID-19 protocol changes.
Results:
From March 2019 to May 2020, a total of 196 patients were enrolled in the PSP.
|
|
Number |
|
Enrolled Patients |
196 |
|
Number of Participating Physicians |
24 |
|
Number of Participating Intuitions |
21 |
On average, patient’s postcodes were located 98 km from the referring hospital. In NSW specifically where the majority of patients were located, this number was approximately 87 km.
During the initial COVID-19 pandemic period (March 1, 2020 - May 31, 2020), there were a total of 12 patients enrolled in the program.
In March 2020 strict pre-visit screening protocols were introduced to safeguard patient and nurse safety as a result of the emerging pandemic. These measures included mandated use of Personal protective equipment (PPE), sanitation practices in-line with government regulations and development of appropriate procedures in the case of a positive COVID-19 result.
Conclusions:
The PSP and home infusion service has provided an additional approach to patient support for patients with cancer. The program has reduced the amount of patient hospital visits required to undergo infusions. During the COVID-19 period, the program offered an option for clinicians to avoid patient’s attending hospitals for infusions.